SRF-Funded Glucosepane Paper in Science
NEW STUDY FUNDED BY SENS RESEARCH FOUNDATION SHEDS GREATER LIGHT ON DIABETES AND THE AGING PROCESS
New Synthetic Process Developed at Yale University Will Allow Scientists to Examine a Critical Link Associated with Diabetes, Inflammation and Human Aging
MOUNTAIN VIEW, Calif. — October 15, 2015 — A new study funded by the SENS Research Foundation sheds greater light on diabetes and aging through a synthetic process developed at Yale University. The new process will allow researchers to study glucosepane, a key molecule involved in diabetes, inflammation, and human aging.
Glucosepane is considered to be a critical chemical link in both diabetes and aging. It is also an independent risk factor for long-term microvascular complications in diabetes. In an article published this week in the journal Science, senior author David Spiegel and his colleagues describe the new synthesis, as well as a new synthetic methodology, which may have applications beyond the current research.
Spiegel, a professor of chemistry and pharmacology at Yale, says that with access to synthetic glucosepane, scientists will now be able to generate tools to examine the role this molecule plays in human health and perhaps, develop molecules to inhibit or reverse its formation.
Glucosepane contains a rare isomer of imidazole, which has never before been observed in natural molecules, other than those in the glucosepane family. Spiegel and his colleagues developed a new methodology for synthesizing this imidazole form that requires only eight steps.
“We are extremely proud to have supported this project and the developments leading to better insights on diabetes and aging,” said Mike Kope, CEO, SENS Research Foundation. "To have Science recognize the accomplishment of Dr. Spiegel and his team doesn't just demonstrate the value of our contribution to medical research; it helps raise awareness that the SENS Research Foundation approach can lead to better insights about aging and age related disease."
The first author of the study is Cristian Draghici, a former postdoctoral researcher at Yale who is now at the Broad Institute of MIT and Harvard. Tina Wang, a former Ph.D student at Yale who is now at Harvard, is the other co-author.
About SENS Research Foundation (SRF)
SENS Research Foundation is a 501(c)(3) nonprofit that works to research, develop, and promote comprehensive regenerative medicine solutions for the diseases of aging. SRF is focused on a damage repair paradigm for treating the diseases of aging, which it advances through scientific research, advocacy, and education. SENS Research Foundation supports research projects at universities and institutes around the world with the goal of curing such age-related diseases as heart disease, cancer, diabetes and Alzheimer’s disease. Educating the public and training researchers to support a growing regenerative medicine field are also major endeavors of the organization that are being accomplished though advocacy campaigns and educational programs. For more information, visit www.sens.org.